<DOC>
	<DOCNO>NCT00895037</DOCNO>
	<brief_summary>The purpose observational study describe incidence adverse event among patient treat Refacto AF usual health care setting Germany Austria .</brief_summary>
	<brief_title>Study Evaluating Pharmacovigilance Of Refacto AF</brief_title>
	<detailed_description>Non-interventional study : subject select accord usual clinical practice physician</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Patients hemophilia A severity already receive start treatment ReFacto AF . Patients Hemophilia A treated product Refacto AF .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>